Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy

Go back to Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy
(NASDAQ: NUWE) Delayed: 0.86 -0.04 (4.44%)
Previous Close $0.90    52 Week High
Open $0.88    52 Week Low
Day High $0.88    P/E N/A 
Day Low $0.84    EPS
Volume 297,024